Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Pharmaceuticals, Inc. announced upcoming oral and poster presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress, showcasing data for GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib). The presentations will include final data from the Phase 3 AcceleRET-Lung clinical trial for GAVRETO in NSCLC and real-world data supporting REZLIDHIA's use in patients with R/R mIDH1 AML who have previously received venetoclax. Rigel highlights the continued clinical relevance of its oncology portfolio and its commitment to providing targeted therapies for difficult-to-treat cancers.
RIGEL (NASDAQ: RIGL) director receives 5,750-share Restricted Stock Unit grant
RIGEL Pharmaceuticals Inc. director Alison L. Hannah received a grant of 5,750 Restricted Stock Units (RSUs) as a compensation-related award, not a market purchase. These RSUs, which represent common stock shares, will fully vest on the day before the company's next Annual Meeting, provided she continues her service on the Board of Directors. Following this grant, Hannah's direct holdings in RIGEL Common Stock now total 16,375 shares.
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call - Slideshow (NASDAQ:RIGL) 2026-05-20
Rigel Pharmaceuticals, Inc. published a slide deck in conjunction with an M&A call on May 20, 2026. This article was written by SA Transcripts, Seeking Alpha's team responsible for thousands of quarterly earnings call transcripts. The team aims to share new transcript-related developments with their readers.
Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting
Rigel Pharmaceuticals stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively for future grants and purchases. All three director nominees were elected to serve until the 2029 annual meeting, and stockholders also approved executive compensation on an advisory basis. Ernst & Young LLP was ratified as Rigel's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Rigel (NASDAQ: RIGL) director awarded 5,750 RSUs vesting before annual meeting
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) director Michael Patrick Miller was granted 5,750 Restricted Stock Units (RSUs) as compensation, which will vest fully before the company's next Annual Meeting, provided he continues his service on the Board. This transaction, detailed in a Form 4 filing, is an equity grant at a price of $0.00 per share, increasing his direct holdings to 5,937 shares of common stock. The filing clarifies this is a grant, not a market purchase or sale of shares.
Board member gets 5,750 RSUs at Rigel Pharmaceuticals (RIGL)
Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units (RSUs) as an equity award, which will vest upon him continuing service on the board until the day before the company's next annual meeting. These RSUs were granted at no cost, and following this award, Frohlich beneficially owns 7,000 shares of Rigel's common stock. This transaction is considered a compensation grant rather than a market purchase.
RIGEL (RIGL) director Lapointe granted 5,750-share RSU-based stock award
RIGEL Pharmaceuticals Inc. director Anthony Gregg Lapointe was granted a 5,750-share Restricted Stock Unit (RSU) award, reported in a Form 4 SEC filing. These shares, valued at $0.00 each, will fully vest on the day before the company's next Annual Meeting, contingent on his continued service on the Board of Directors. Following this award, Lapointe's direct holdings in RIGEL Common Stock now total 18,250 shares.
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU
Rigel Pharmaceuticals (RIGL) has seen an 11.4% stock increase after securing exclusive global licensing for VEPPANU, an FDA-approved breast cancer drug. This acquisition marks VEPPANU as Rigel’s fourth commercial product and its first approved PROTAC, significantly expanding its oncology portfolio. Despite the positive development, the company's investment narrative still highlights concentration risk in its revenue streams and the presence of non-cash items in earnings.
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU
Rigel Pharmaceuticals (RIGL) saw its stock rise by 11.4% after announcing an exclusive global licensing agreement for VEPPANU, an FDA-approved oral PROTAC for certain advanced breast cancers. This addition, Rigel's fourth commercial product, is expected to reshape its oncology focus, though near-term revenue remains concentrated in a few products. The company reaffirmed its 2026 guidance, expecting $275 to $290 million in revenue and positive net income, and analysts project further revenue growth and an implied fair value significantly above its current price.
Armistice Capital (RIGL) reports 1.28M shares, 6.93% stake
Armistice Capital, LLC and Steven Boyd have jointly disclosed a 6.93% stake in Rigel Pharmaceuticals Inc. (RIGL), amounting to 1.28 million shares of Common Stock. This passive investment is held by Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power over the shares through an Investment Management Agreement. The Schedule 13G filing indicates the ownership position as of March 31, 2026, with the document signed on May 15, 2026.
Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU
Rigel Pharmaceuticals has signed an exclusive global license agreement to develop, manufacture, and commercialize VEPPANU (vepdegestrant). This strategic move aims to strengthen Rigel's position in the oncology sector. The company is set to release its Q1 2026 financial results on May 5, which will include a business update related to these developments.
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals, Inc. announced that its Chief Financial Officer, Dean Schorno, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m. ET. The presentation will cover the company's focus on hematologic disorders and cancer, including its marketed products and pipeline. A live webcast and archived recording will be available on the company's investor relations website.
Blood disorder and cancer biotech Rigel to give overview at RBC event
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that CFO Dean Schorno will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on May 19th at 9:30 a.m. ET in New York. The presentation will feature topics relevant to its hematologic disorders and cancer portfolio, with a live webcast available on Rigel's Investor Relations website. This event follows recent positive news for Rigel, including profitable Q1 2026 results and a significant licensing agreement.
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?
Rigel Pharmaceuticals' stock rose 20.5% after securing exclusive global commercialization rights for VEPPANU (vepdegestrant) from Arvinas and Pfizer. VEPPANU is an FDA-approved oral PROTAC for ESR1-mutated metastatic breast cancer. This deal significantly reshapes Rigel's investment narrative by adding an FDA-approved oncology product, though it also introduces near-term execution risks related to its successful U.S. launch and integration.
RIGL Maintained by Citigroup -- Price Target Raised to $81.00
Citigroup has maintained a 'Buy' rating for Rigel Pharmaceuticals (RIGL) and increased its price target from $69.00 to $81.00, reflecting confidence in the company's growth potential. Despite this positive analyst outlook, GuruFocus indicates that RIGL is currently 15.7% overvalued based on its GF Value™, suggesting caution for investors. The company's GF Score™ of 81/100 points to strong overall performance, particularly in financial strength and momentum, though profitability shows areas for improvement.
Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu | PharmExec
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, a novel cancer therapy, involving an upfront payment and potential future milestones. Additionally, Eli Lilly released trial data demonstrating that patients maintained significant weight loss after transitioning from higher-dose injectable GLP-1 therapies to Foundayo or lower-dose Zepbound. The article also includes insights on pharmaceutical expertise, emphasizing the importance of recognizing when a "reset" is needed.
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
Rigel Pharmaceuticals has secured exclusive global rights to Veppanu (vepdegestrant), an FDA-approved PROTAC therapy for ESR1-mutated metastatic breast cancer, through an $85 million agreement with Arvinas and Pfizer. Veppanu works by degrading disease-causing proteins, offering a novel approach to overcome endocrine resistance in patients whose disease has progressed after previous therapies. Clinical trials demonstrated a significant 43% reduction in progression or death risk compared to fulvestrant, positioning Veppanu as a crucial new treatment option.
Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position
Rigel Pharmaceuticals' latest earnings report showed a significant discrepancy between its reported profit and free cash flow, indicated by a high accrual ratio of 1.68. The company received a substantial one-off tax benefit of US$242m, which artificially inflated its statutory profit of US$364.2m while its free cash flow was only US$79m. These factors suggest that Rigel's underlying earnings power might be weaker than its reported profits indicate, raising concerns about future profitability without this non-recurring tax benefit.
Rigel takes up the Veppanu challenge | ApexOnco - Clinical Trials news and analysis
Rigel Pharmaceuticals has licensed the oral estrogen degrader Veppanu from Arvinas and Pfizer for an upfront payment of $70 million, plus transition payments and milestones. This deal comes after Veppanu's potential was re-evaluated, focusing on second-line ESR1-mutant breast cancer rather than first-line, where it previously lacked prospects. The acquisition adds Veppanu to Rigel's growing oncology portfolio, much of which has been in-licensed, similar to their previous successful acquisition of Gavreto.
Arvinas And Pfizer Enter Into A Transaction With Rigel Pharmaceuticals For The Exclusive Global Rights Of Veppanu
Arvinas and Pfizer have entered into a transaction with Rigel Pharmaceuticals to secure the exclusive global rights for Veppanu. This brief article from Refinitiv reports on the agreement between the three pharmaceutical companies. Further details of the transaction were not immediately provided, stating it was less than a 1-minute read.
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU™ (vepdegestrant), the first and only FDA-approved oral PROTAC for advanced or metastatic breast cancer. This agreement makes VEPPANU Rigel's fourth commercial product, aiming to accelerate revenue growth. The deal involves an upfront payment of $70 million, an additional $15 million upon transition activities, and potential regulatory and commercial milestones up to $320 million for Arvinas and Pfizer.
Number of shareholders of Rigel Pharmaceuticals, Inc. – SWB:RI2
This article provides details about Rigel Pharmaceuticals, Inc. (SWB:RI2), specifically focusing on its financial information, including the number of shareholders. It indicates that the market was closed at the time of publication and offers various data services and resources related to the company.
Soleus files 5.2% stake in Rigel Pharmaceuticals (RIGL)
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a beneficial ownership stake of 5.2% in Rigel Pharmaceuticals (RIGL), acquiring 968,108 shares of common stock. This disclosure was made in a Schedule 13G SEC filing, indicating a passive investment. The percentage is based on 18,502,080 shares outstanding as of April 30, 2026, as per Rigel's latest Form 10-Q.
Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High‑Earnings Narrative
Rigel Pharmaceuticals (RIGL) reported Q1 2026 revenue of US$58.8 million and basic EPS of US$0.47, amidst an impressive trailing 12-month earnings growth. However, this profit growth significantly outpaced modest 6.3% revenue growth, raising questions about the sustainability of its earnings, especially due to a high share of non-cash collaboration income. Analysts forecast a substantial decline in earnings over the next three years, contrasting with a bullish narrative that hinges on future commercial expansion and higher valuation.
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Cuts Target Price to $69
Citi has reiterated its Buy rating on Rigel Pharmaceuticals (RIGL.US) but has lowered its price target to $69. This adjustment indicates a continued positive outlook on the company despite a revised valuation.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q1 2026 net product sales of $54.9 million, a 26% increase year-over-year, and maintained its 2026 revenue guidance of $275 million to $290 million. The company is progressing with its R289 program for lower-risk MDS, with data expected by year-end, and is actively seeking late-stage in-licensing or acquisition opportunities. Rigel also announced the termination of its collaboration with Lilly for ocodusertib but clarified it doesn't impact their financial outlook, and restructured its debt agreement for increased financial flexibility.
Rigel Pharmaceuticals (Nasdaq:RIGL) - Stock Analysis
This Simply Wall St analysis provides a comprehensive overview of Rigel Pharmaceuticals (Nasdaq:RIGL), highlighting its market position, valuation, and recent financial performance. The report indicates that RIGL is currently trading significantly below its estimated fair value, despite forecasts of declining earnings in the coming years. It also details recent earnings reports, guidance, significant clinical trial data for its key drugs like GAVRETO and REZLIDHIA, and insider transactions.
Rigel Pharmaceuticals (RIGL) Q1 EPS Compression Tests Bullish High‑Earnings Narrative
Rigel Pharmaceuticals (RIGL) reported Q1 2026 revenue of US$58.8 million and basic EPS of US$0.47, with trailing 12-month revenue of US$299.8 million and significant earnings growth. Despite strong trailing earnings, revenue growth was modest at 6.3%, and analysts forecast a 33% annual EPS decline over the next three years, raising questions about the durability of current profits, especially due to high non-cash earnings. The stock trades at a low 1.4x P/E, presenting a conflict between a bullish narrative of potential growth and analyst expectations of declining earnings.
Rigel Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its Q1 2026 earnings, reporting an EPS of $0.44, missing estimates by $0.43, and revenue of $58.82M, missing by $3.58M. This financial update was provided in their earnings call presentation published on May 5, 2026.
Rigel Pharmaceuticals : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)
Rigel Pharmaceuticals released its quarterly report for the period ending March 31, 2026, detailing financial results, product sales, and pipeline updates. The company reported increased net product sales for TAVALISSE, REZLIDHIA, and GAVRETO, alongside developments in its R289 IRAK1/4 inhibitor program and collaborations for olutasidenib. The report also addresses the termination of its global strategic partnership with Lilly and changes to its credit agreement with MidCap.
Rigel Pharmaceuticals (RIGL) lags Q1 earnings and revenue estimates
Rigel Pharmaceuticals (RIGL) reported its Q1 results, missing both earnings and revenue estimates. This financial performance indicates a challenging start to the year for the company. The specific details of the earnings and revenue figures were not provided in this snippet.
Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c
Rigel Pharmaceuticals (RIGL) announced Q1 EPS of 44 cents, falling short of the consensus estimate of 87 cents. The company also reported Q1 revenue of $58.8 million, below the consensus of $62.4 million. Despite missing estimates, Rigel's President and CEO, Raul Rodriguez, highlighted continued year-over-year growth from their commercial portfolio and financial discipline, driving another quarter of profitability.
Rigel (NASDAQ: RIGL) grows Q1 2026 drug sales, reaffirms 2026 outlook
Rigel Pharmaceuticals reported strong Q1 2026 revenues of $58.8 million, driven by a 26% increase in net product sales across its hematology-oncology portfolio, including TAVALISSE, GAVRETO, and REZLIDHIA. Despite higher R&D and commercial spending leading to a lower net income of $8.7 million compared to the previous year, the company reaffirmed its 2026 revenue guidance of $275-$290 million and expects positive full-year net income. Rigel also provided updates on its clinical pipeline, particularly the advancement of its R289 study.
Earnings call transcript: Rigel Pharmaceuticals Q1 2026 sees revenue growth, stock dips
Rigel Pharmaceuticals reported a 26% year-over-year increase in Q1 2026 net product sales, reaching $54.9 million, primarily driven by strong TAVALISSE sales. Despite the revenue growth, the company's stock dipped by 1.09% due to a 23.7% decrease in net income, attributed to rising R&D and commercial expenses. Rigel maintains its full-year 2026 revenue guidance and is advancing its R289 program in lower-risk MDS, with data expected by year-end.
Hussman Strategic Advisors Inc. Buys New Shares in Rigel Pharmaceuticals, Inc. $RIGL
Hussman Strategic Advisors Inc. has acquired 52,500 shares of Rigel Pharmaceuticals (NASDAQ:RIGL) in Q4, valued at approximately $2.25 million, increasing institutional ownership to 66.23%. Despite missing EPS consensus for Q4 with $1.14 against an expected $1.33, the company reported strong profitability metrics and revenue that slightly beat estimates. Rigel Pharmaceuticals currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $45.67.
Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 55,200 Rigel Pharmaceuticals, Inc. $RIGL
Universal Beteiligungs und Servicegesellschaft mbH recently acquired 55,200 shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) in the fourth quarter, a stake valued at approximately $2.36 million, bringing institutional ownership in Rigel to 66.23%. This comes as corporate insiders own 10.47% of the stock, with a director recently selling 4,000 shares. Analysts currently rate RIGL as a "Moderate Buy" with an average price target of $45.67, despite the company missing its EPS estimates but exceeding revenue expectations in its last quarterly report.
Q1 2026 results and business update set for May 5, Rigel Pharmaceuticals confirms
Rigel Pharmaceuticals is scheduled to release its first-quarter 2026 financial results and provide a business update on May 5. The announcement is highly anticipated by investors and analysts keen to understand the biopharmaceutical firm's performance and strategic direction. Further details regarding the report will be available through the company's official channels.
Rigel Pharmaceuticals (RIGL) to report Q1 results: Wall Street expects earnings growth
This article announces that Rigel Pharmaceuticals (RIGL) is expected to report its Q1 results, with Wall Street anticipating earnings growth. The report will likely detail the company's financial performance and provide insights into its future outlook.
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. This will be followed by a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast will be accessible via their investor relations website, www.rigel.com, and will be archived for 90 days.
Rigel Pharmaceuticals (RIGL) to Release Earnings on Tuesday
Rigel Pharmaceuticals (NASDAQ:RIGL) is scheduled to release its Q1 2026 earnings after market close on Tuesday, May 5th, with analysts projecting $0.86 EPS and $63.585 million in revenue. The company's stock was trading up 1.7% at $31.04 midday, with a market capitalization of $573.6 million. Analysts currently have an average "Moderate Buy" rating and a consensus target price of $45.67 for RIGL.
Is the options market predicting a spike in Rigel Pharmaceuticals stock?
This article examines whether the options market is indicating a potential upward movement in Rigel Pharmaceuticals' stock. It suggests that options trading activity can sometimes foreshadow significant price changes in a company's shares. The focus is purely on the predictive signals from options data concerning Rigel Pharmaceuticals.
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Following the announcement, Rigel senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast will be accessible from the Investor Relations section of the company's website.
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced an upcoming conference call and webcast to report its first-quarter 2026 financial results. The event is scheduled for Tuesday, May 5, 2026, after market close, with a live conference call and webcast at 4:30 p.m. Eastern Time. Senior management will discuss the results and provide a business update, with details for access available on Rigel's investor relations website.
Rigel Pharmaceuticals (RIGL) to Report Q1 Results: Wall Street Expects Earnings Growth
Rigel Pharmaceuticals (RIGL) is preparing to release its Q1 results, with Wall Street analysts projecting an increase in earnings and higher revenues year-over-year. The consensus EPS estimate is $0.74 per share, representing a 17.5% increase, on expected revenues of $60.26 million, up 13%. However, the company's Zacks Earnings ESP is negative (-28.38%), and its recent earnings surprise history shows varied results, suggesting a conclusive prediction for an earnings beat is difficult.
Rigel to release first-quarter results after close, then host webcast
Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will report Q1 2026 financial results after market close on Tuesday, May 5, 2026. Senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide business updates. The call details and webcast information are provided for investors and media.
Is the options market predicting a spike in Rigel Pharmaceuticals stock?
The article investigates whether options trading activity suggests an impending spike in Rigel Pharmaceuticals stock. It aims to analyze market sentiment and potential price movements based on options data. The content will likely delve into specific options contracts, volumes, and open interest to support its findings.
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Cuts Target Price to $40
Piper Sandler has reiterated its Hold rating on Rigel Pharmaceuticals (RIGL.US) but has reduced its target price for the stock from $45 to $40. This adjustment in target price suggests a revised outlook on the company's valuation by the analyst firm.
Behavioral Patterns of RIGL and Institutional Flows
This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models to identify behavioral patterns and institutional flows. It highlights weak near-term sentiment but strong mid and long-term outlooks, presenting specific trading strategies (Position, Momentum Breakout, Risk Hedging) with outlined entry/target/stop-loss points. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for RIGL.
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals Stock?
The options market suggests a potential significant move for Rigel Pharmaceuticals (RIGL) due to high implied volatility in its Jun 18, 2026 $23 Call options. Despite this, analysts currently rate the stock as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates. This situation may appeal to options traders looking to sell premium.
RIGL Price Today: Rigel Pharmaceuticals Inc. (New) Stock Price, Quote & Chart | MEXC
This article provides current stock information for Rigel Pharmaceuticals Inc. (RIGL), including its live price, key market data, and recent performance trends. It also details the company's business, pipeline products, and offers a guide on how to buy RIGL stock on MEXC. The FAQ section addresses common investor questions regarding share price, performance, valuation, and dividends.
